Leadership Overview
Amgen has 9 executives leading key functions including strategic planning, information technology, financial management, and human resources.
Committed to pioneering scientific innovation, Amgen delivers life-saving biotechnology solutions while maintaining a rigorous focus on patient access and global operational excellence across the pharmaceutical landscape.
Committed to pioneering scientific innovation, Amgen delivers life-saving biotechnology solutions while maintaining a rigorous focus on patient access and global operational excellence across the pharmaceutical landscape.
Leadership Roles at Amgen
Marianela Capelli - Chief Financial Officer (Argentina)
Marianela Capelli, the Chief Financial Officer (Argentina) at Amgen, oversees all fiscal operations and financial reporting within the South American market. Capelli manages capital allocation strategies that support regional growth and ensure compliance with local regulatory frameworks. By directing financial planning and analysis, the Chief Financial Officer (Argentina) provides the necessary insights to sustain the company's competitive edge in the pharmaceutical industry. This leadership role involves managing currency fluctuations and economic volatility to protect the company's bottom line. Marianela Capelli coordinates with global finance teams to ensure that regional performance aligns with the broader corporate objectives of the organization. Through meticulous oversight of regional budgets and investment portfolios, the Chief Financial Officer (Argentina) secures the financial health required to expand the company's footprint across the Latin American region.
Peter Griffith - Executive VP & Chief Financial Officer
Peter Griffith, the Executive VP & Chief Financial Officer at Amgen, directs the global financial strategy and capital structure of the entire organization. Griffith manages investor relations, corporate treasury, and long-term financial planning to support the company's massive research and development investments. By overseeing the allocation of resources across international markets, the Executive VP & Chief Financial Officer ensures that the company maintains the liquidity necessary for sustained innovation. This leadership role involves constant engagement with the Board to communicate financial performance and strategic growth opportunities. Peter Griffith drives the fiscal discipline required to maintain the company's status as a premier biotechnology entity. Through the management of global tax strategies and financial risk assessment, the Executive VP & Chief Financial Officer provides the stability needed to navigate the complex and capital-intensive pharmaceutical landscape.
Stephanie Camstra - Strategic Planning Operations, Patient Access & Reimbursement To Chief of Staff (US) & Vice President
Stephanie Camstra, the Strategic Planning Operations, Patient Access & Reimbursement To Chief of Staff (US) & Vice President at Amgen, directs critical initiatives regarding patient affordability and market access. Camstra architects complex frameworks that streamline reimbursement pathways for biotechnology therapies across the United States. By aligning internal strategic planning with external regulatory requirements, the Vice President ensures that patients receive timely access to essential medications. This leadership role involves constant collaboration with commercial teams to optimize the delivery of high-value pharmaceutical products. Stephanie Camstra maintains a focus on operational efficiency, ensuring that the organization meets its ambitious growth targets while navigating the intricacies of the American healthcare system. Through rigorous data analysis and cross-functional coordination, the Vice President drives the long-term sustainability of the company's patient-centric mission.
Scott Skellenger - Senior VP & Chief Information Officer
Scott Skellenger, the Senior VP & Chief Information Officer at Amgen, manages the global digital infrastructure supporting advanced pharmaceutical research and manufacturing. Skellenger architects secure, scalable cloud environments that enable data-driven decision-making across the entire enterprise. By overseeing the integration of artificial intelligence into drug discovery pipelines, the Chief Information Officer accelerates the speed at which new therapies reach the market. This leadership role requires constant alignment with global cybersecurity standards to protect sensitive intellectual property and patient data. Scott Skellenger drives the digital transformation of the company, ensuring that information systems remain resilient against evolving technological threats. Through the implementation of robust enterprise resource planning tools, the Chief Information Officer optimizes internal workflows, ultimately supporting the company's position as a leader in the biotechnology sector.
Katherine Rizos - Director, Strategic Planning & Operations & To The Chief of Staff & Chief Information Officer
Katherine Rizos, the Director, Strategic Planning & Operations & To The Chief of Staff & Chief Information Officer at Amgen, coordinates the operational alignment between executive leadership and information technology departments. Rizos architects internal communication protocols that ensure the Chief Information Officer receives actionable data for strategic decision-making. By managing the operational cadence of the office, the Director facilitates the execution of high-priority projects across the global organization. This leadership role involves bridging the gap between technical infrastructure requirements and long-term business goals. Katherine Rizos drives the efficiency of the executive office, ensuring that resources are directed toward the most impactful biotechnology initiatives. Through the synchronization of cross-departmental workflows, the Director supports the company's mission to deliver innovative therapies while maintaining a lean and responsive operational structure.
Eric Chamblee - Director. Chief of Staff for Senior Vice President Commercial, Obesity and Related Conditions
Eric Chamblee, the Director. Chief of Staff for Senior Vice President Commercial, Obesity and Related Conditions at Amgen, manages the strategic operations for the commercial division focused on metabolic health. Chamblee architects the go-to-market strategies for new therapies targeting obesity and related chronic conditions. By overseeing the coordination of commercial teams, the Director ensures that the company effectively communicates the value of its pharmaceutical products to healthcare providers. This leadership role involves analyzing market trends to identify growth opportunities within the competitive landscape of metabolic medicine. Eric Chamblee drives the execution of commercial objectives, ensuring that the organization meets its revenue targets while improving patient outcomes. Through the management of complex cross-functional projects, the Director supports the company's commitment to addressing significant public health challenges through innovative biotechnology solutions.
Valentina Guarino - Manager, Combination Product Operations (Chief People Officer)
Valentina Guarino, the Manager, Combination Product Operations (Chief People Officer) at Amgen, directs the human capital strategy specifically for the teams developing complex combination products. Guarino architects talent development programs that ensure the organization retains the specialized engineering and scientific expertise required for advanced drug delivery systems. By overseeing the cultural integration of technical teams, the Manager, Combination Product Operations (Chief People Officer) fosters an environment of innovation and collaboration. This leadership role involves aligning workforce capabilities with the evolving demands of the biotechnology manufacturing sector. Valentina Guarino drives the recruitment and retention of top-tier talent, ensuring that the company maintains its competitive advantage in product development. Through the implementation of performance management systems, the Manager, Combination Product Operations (Chief People Officer) supports the company's mission to deliver high-quality, patient-focused medical devices.
Rene Marquina - Senior Engineer & Chief People Officer, Risk Engineering
Rene Marquina, the Senior Engineer & Chief People Officer, Risk Engineering at Amgen, manages the safety protocols and human capital strategies within the risk engineering department. Marquina architects robust risk assessment frameworks that protect the integrity of the company's manufacturing processes. By overseeing the training and development of engineering staff, the Senior Engineer & Chief People Officer, Risk Engineering ensures that the workforce remains proficient in the latest safety and compliance standards. This leadership role involves identifying potential operational hazards and implementing mitigation strategies to ensure continuous production. Rene Marquina drives the culture of safety and excellence, ensuring that the company maintains its reputation for high-quality pharmaceutical manufacturing. Through the integration of engineering expertise and human resources management, the Senior Engineer & Chief People Officer, Risk Engineering supports the company's commitment to operational reliability and patient safety.
Lisa Fries - Team Captain
Lisa Fries, the Team Captain at Amgen, directs the daily operational activities of specialized research and development units. Fries architects the workflow processes that allow scientific teams to conduct rigorous clinical trials and laboratory experiments. By overseeing the coordination of project timelines, the Team Captain ensures that research milestones are met with precision and scientific integrity. This leadership role involves fostering a culture of excellence and accountability within the laboratory environment. Lisa Fries drives the collaborative efforts of the team, ensuring that individual contributions align with the broader goals of the biotechnology division. Through the management of daily operations and resource allocation, the Team Captain supports the company's commitment to scientific discovery and the development of groundbreaking pharmaceutical therapies that address unmet medical needs.
Explore Leadership Teams in Manufacturing
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in Phase III clinical trials to treat glabellar (frown) lines, as well as in Phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark,...
Company Leadership
SK
MA
Emcure Pharmaceuticals Limited is a global pharmaceutical company engaged in the research, development, manufacturing, and marketing of a broad range of pharmaceutical products and healthcare solutions. Headquartered in Pune, India, the organization operates as an international pharmaceutical enterprise with a strong presence in both domestic and global healthcare markets. The company focuses on delivering innovative and affordable medicines that address a wide spectrum of medical conditions and therapeutic needs across the healthcare sector. The organization is driven by a research-focused strategy that emphasizes innovation, scientific advancement, and the development of effective therapeutic solutions. Through its research and development capabilities, Emcure Pharmaceuticals works to discover and formulate medicines that address unmet medical needs and improve patient outcomes. The company’s research initiatives focus on areas such as complex generics, biosimilars, biologics, and specialized pharmaceutical formulations. These research efforts allow the organization to continuously introduce improved therapies and drug delivery systems designed to enhance treatment effectiveness and patient safety.
Company Leadership SM
DG
Humanetics Corporation is a clinical-stage pharmaceutical company engaged in the accelerated discovery, development, and commercialization of proprietary drugs in markets with urgent and unmet needs with a focus on medical countermeasures, radiation modulators for oncology and inflammatory lung diseases.
Company Leadership BL
KN
SC
AS
PT. Inertia Utama is a company that works within the pharmaceutical industry. The company is based in Tangerang Selatan, Indonesia.
Company Leadership HS
WW
FS
Frequently Asked Questions Regarding Amgen Top Executives and Leadership Team
Unlock more people and company data
